Abzena, a Cambridge, UK-based life sciences company providing services and technologies that enable the development of biopharmaceutical products, has appointed Dr Jim Mills as Vice President, Technical Operations.
In this new position Mills will take a leading role in the development of the Group’s strategy to support its partners’ access to Abzena’s technologies for biopharmaceutical development, as well as providing support for the commercial activities of the group.
Most recently Mills was CEO of Cantab Biopharmaceuticals, which he joined in 1997, initially to work in process development. He took on roles with increasing levels of responsibility in biopharmaceutical manufacturing before becoming Director of Operations following the acquisition of Cantab by Xenova in 2007 and became CEO in 2010 when the company was taken over by Celtic Pharma Holdings.
